Haussier
Pfizer's TUKYSA regimen approved for HER2+ breast cancer maintenance treatment.
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
Pfizer's TUKYSA regimen, combined with trastuzumab and pertuzumab, has been approved by the FDA as a front-line maintenance treatment for adults with HER2-positive metastatic breast cancer. This approval is based on the Phase 3 HER2CLIMB-05 trial, which demonstrated a 35.9% reduction in the risk of disease progression or death compared to placebo. Additionally, Pfizer will present 57 abstracts at IDWeek 2026, showcasing advancements in infectious disease research, including data on pneumococcal vaccines and RSV treatments.
Points clés
- FDA approves TUKYSA regimen for HER2+ metastatic breast cancer maintenance.
- Pfizer to present 57 abstracts at IDWeek 2026 on infectious disease advancements.
Sources
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.
